• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献>>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

Recombinant human adenovirus type 5 promotes anti-tumor immunity via inducing pyroptosis in tumor endothelial cells

摘要Recombinant human type 5 adenovirus(H101)is an oncolytic virus used to treat nasopharyngeal carcinoma.Owing to the deletion of the E1B-55kD and E3 regions,H101 is believed to selectively inhibit nasopharyngeal carcinoma.Whether H101 inhibits other type of tumors via different mechanisms remains unclear.In this study we investigated the effects of H101 on melanomas.We established B16F10 melanoma xenograft mouse model,and treated the mice with H101(1×108 TCID50)via intratumoral injection for five consecutive days.We found that H101 treatment significantly inhibited B16F10 melanoma growth in the mice.H101 treatment significantly increased the infiltration of CD8+T cells and reduced the proportion of M2-type macrophages.We demonstrated that H101 exhibited low cytotoxicity against B16F10 cells,but the endothelial cells were more sensitive to H101 treatment.H101 induced endothelial cell pyroptosis in a caspase-1/GSDMD-dependent manner.Furthermore,we showed that the combination of H101 with the immune checkpoint inhibitor PD-L1 antibody(10 mg/kg,i.p.,every three days for three times)exerted synergic suppression on B16F10 tumor growth in the mice.This study demonstrates that,in addition to oncolysis,H101 inhibits melanoma growth by promoting anti-tumor immunity and inducing pyroptosis of vascular endothelial cells.

更多
广告
作者 Zhi-ming Wang [1] Meng-kai Li [1] Qing-ling Yang [2] Shi-xin Duan [1] Xin-yi Lou [1] Xin-yi Yang [1] Ying Liu [1] Yu-wen Zhong [1] Yu Qiao [2] Zi-shu Wang [3] Lei Sun [1] Feng Qian [1] 学术成果认领
作者单位 Shanghai Frontiers Science Center of Drug Target Identification and Delivery;Engineering Research Center of Cell & Therapeutic Antibody,Ministry of Education,School of Pharmaceutical Sciences;National Key Laboratory of Innovative Immunotherapy,Shanghai Jiao Tong University,Shanghai 200240,China [1] Anhui Province Key Laboratory of Cancer Translational Medicine,Bengbu Medical University,Bengbu 233030,China [2] Department of Medical Oncology,Anhui Province Key Laboratory of Translational Cancer Research,First Affiliated Hospital of Bengbu Medical College,Bengbu Medical University,Bengbu 233004,China [3]
栏目名称
DOI 10.1038/s41401-024-01349-x
发布时间 2024-12-18
提交
  • 浏览0
  • 下载0
中国药理学报(英文版)

中国药理学报(英文版)

2024年45卷12期

2646-2656页

SCIMEDLINEISTICCSCDCABP

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷